<a href="#hui-cai">Hui Cai</a>, Program Chair, VP and Head of Content, WuXi AppTec
<a href="#katie-clapp">Katie Clapp</a>, President &amp; Co-Founder, FRAXA Research Foundation

Welcome

<a href="#katie-clapp">Katie Clapp</a>, President &amp; Co-Founder, FRAXA Research Foundation
<a href="#alison-singer">Alison Singer</a>, President, Autism Science Foundation
<a href="#wendy-bruce">Wendy Bruce</a>, Executive Director, Fragile X Association of Australia
<a href="#yinan-ma">Yinan Ma</a>, VP, Fragile X Association of China
<a href="#karen-kelm">Karen Kelm</a>, Board Member, Fragile X Foundation of Canada
<a href="#shalini-kedia">Shalini Kedia</a>, Chairperson, Fragile X Society – India
<a href="#sabrina-muggiati">Sabrina Muggiati</a>, Creator of the Eu Digo X Program – Brazil
<a href="#paula-gómez-ortega">Paula Gómez Ortega</a>, Coordinator, Fragile X Syndrome Parent&#8217;s Group – Argentina
<a href="#sandz-fraser">Sandz Fraser</a>, Coordinator, Fragile X South Africa; Owner &amp; Trustee, FiX Africa Special Needs Homeschool
<a href="#nazhi-tabatadze">Nazhi Tabatadze</a>, Clinic coordinator at Fragile X Center, Georgia
<a href="#andrea-lee">Andrea Lee</a>, Executive Director, Fragile X New Zealand

Collaboration and the voices of the patient advocacy groups 

<a href="#craig-erickson">Craig Erickson</a>, Professor of Clinical Psychiatry, Cincinnati Children&#8217;s Hospital and the University of Cincinnati College of Medicine
<a href="#randi-hagerman">Randi Hagerman</a>, Medical Director, MIND Institute; Distinguished Professor of Pediatrics, Endowed Chair, Fragile X Research, UC Davis Health
<a href="#elizabeth-berry-kravis">Elizabeth Berry-Kravis</a>, Professor of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center
Moderator: <a href="#ted-brown">Ted Brown</a>, President, Fragile X Association of Australia

Current clinical studies and practice

Patient story: 3 Australian families

<a href="#neil-thompson">Neil Thompson</a>, CSO, Healx
<a href="#mark-bear">Mark Bear</a>, Professor of Neuroscience, Picower Institute for Learning and Memory, MIT
<a href="#mark-gurney">Mark Gurney</a>, Chairman &amp; CEO, Tetra Therapeutics
<a href="#walter-kaufmann">Walter Kaufmann</a>, CMO, Anavex Life Sciences; Adjunct Professor of Human Genetics, Emory University
<a href="#charles-large">Charles Large</a>, CEO, Autifony Therapeutics
Moderator:<a href="#richard-soll"> Richard Soll</a>, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec

New directions in Fragile X Syndrome therapeutics

Patient story: The Goss family

<a href="#michael-tranfaglia">Michael Tranfaglia</a>, Medical Director &amp; CSO, FRAXA Research Foundation
<a href="#alison-singer">Alison Singer</a>, President, Autism Science Foundation
<a href="#nahum-sonenberg">Nahum Sonenberg</a>, Professor &amp; Gilman Cheney Chair in Biochemistry, Goodman Cancer Research Centre, McGill University
<a href="#peter-kind">Peter Kind</a>, Director, Simons Initiative for the Developing Brain, Patrick Wild Centre; Professor of Developmental Neuroscience, University of Edinburgh
<a href="#sumantra-chattarji">Sumantra Chattarji</a>, Senior Professor, National Centre for Biological Sciences, Tata Institute of Fundamental Science, Bangalore, India
<a href="#patricia-cogram">Patricia Cogram</a>, Associate Professor, Department of Genetics, IEB, Faculty of Science, University of Chile
<a href="#shangzhi-huang">Shangzhi Huang</a>, Professor of Medical Genetics, Peking Union Medical College
<a href="#elizabeth-berry-kravis">Elizabeth Berry-Kravis</a>, Professor of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center

10-year vision 

<a href="#hui-cai">Hui Cai</a>, Program Chair, VP and Head of Content, WuXi AppTec

Closing

WXPRESS1485X973

Fragile X Syndrome: In Pursuit of a Cure

<a href="#michael-hayden">Michael Hayden</a>, Founder &amp; CEO, Prilenia Therapeutics; Killam Professor at the University of British Columbia
Moderator: <a href="#michael-ward">Michael Ward</a>, Global Head of Life Sciences &amp; Healthcare Thought Leadership, Clarivate

Huntington’s Disease: Challenges, Lessons, and Opportunities 

<a href="#karen-anderson">Karen Anderson</a>, Professor, Psychiatry &amp; Neurology, Georgetown University; Director, HD Care, Education and Research Center
<a href="#blair-leavitt">Blair Leavitt</a>, Professor, Department of Medical Genetics and Senior Scientist, Centre for Molecular Medicine and Therapeutics, UBC
<a href="#svein-olaf-osen">Svein Olaf Osen</a>, President, International Huntington Association
<a href="#kristen-powers">Kristen Powers</a>, Executive Producer, Twitch
Moderator: <a href="#richard-soll">Richard Soll</a>, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec

The Evolving Landscape of Care in Huntington’s Disease 

<a href="#irina-antonijevic">Irina Antonijevic</a>, CMO, Triplet Therapeutics
<a href="#ricardo dolmetsch">Ricardo Dolmetsch</a>, President, Research &amp; Development, uniQure
<a href="#aimee-jackson">Aimee Jackson</a>, CSO, Atalanta Therapeutics
Moderator: <a href="#dave-madge">Dave Madge</a>, VP, Research Service Division, WuXi AppTec

New Modalities and Technologies Driving Progress in Huntington’s Disease  

Final_Huntington’s Disease Banner

Winning the War on Huntington’s Disease

<a href="#john-crowley">John Crowley</a>, Chairman &amp; CEO, Amicus Therapeutics
Moderator: <a href="#simone-fishburn">Simone Fishburn</a>, VP &amp; Editor in Chief, BioCentury

Racing against Time in Rare Diseases 

<a href="#tiffany-house">Tiffany House</a>, Chairman &amp; Board Member, International Pompe Association
<a href="#priya-kishnani">Priya Kishnani</a>, C.L. and Su Chen Professor of Pediatrics, Division Chief, Medical Genetics, Duke University Medical Center
<a href="#brad-crittenden">Brad Crittenden</a>, Executive Director, Canadian Association of Pompe
<a href="#jordi-diaz-manera">Jordi Díaz-Manera</a>, Professor of Neuromuscular Disorders, Translational Medicine and Genetics Honorary Consultant in Clinical Genetics, Newcastle University
Moderator:  <a href="#richard-soll">Richard Soll</a>, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec

Closing the Gap in Pompe Disease:  Where Are We Heading 

<a href="#barry-byrne">Barry Byrne</a>, Professor and Associate Chair, Director, Powell Gene Therapy Center, Department of Pediatrics, University of Florida
<a href="#edward-conner">Edward Conner</a>, Site Lead and Division Head of Gene Therapy Medical &amp; Development, Astellas Gene Therapies
<a href="#geoff-mackay">Geoff MacKay</a>, President &amp; CEO, AVROBIO
Moderator: <a href="#david-chang">David Chang</a>, CEO, WuXi Advanced Therapies, WuXi AppTec

Realizing the Promise of Gene Therapy in Pompe 

Closing 

banner-2250X1125-en_Final_2

Progress in Halting Pompe Disease

Banner English Version-Final-1024X512

WuXi Rare Disease Awareness Concert 2021

1152X648-2

WuXi Healthcare Forum 2021

8:00 Welcome 
<a href="#hui-cai">Hui Cai</a>, Forum Chair; VP and Head of Content Division, WuXi AppTec
8:05 Opening Remarks 
<a href="#steve-yang">Steve Yang</a>, Co-CEO, WuXi AppTec
8:10 Rising to the Challenge 
<a href="#michelle-mcmurry-heath">Michelle McMurry-Heath</a>, President &amp; CEO, Biotechnology Innovation Organization 
<a href="#steve-bates">Steve Bates</a>, CEO, BioIndustry Association 
<a href="#arnaud-bernaert">Arnaud Bernaert</a>, Global Head, Platform for Shaping the Future of Health and Healthcare, World Economic Forum 
Session Leader: <a href="#steve-yang">Steve Yang</a>, Co-CEO, WuXi AppTec
8:40 Better Medicines Faster 
<a href="#steve-hitchcock">Steve Hitchcock</a>, Head of Research, Takeda 
<a href="#bahija-jallal">Bahija Jallal</a>, CEO, Immunocore 
<a href="#ameet-nathwani">Ameet Nathwani</a>, CEO, Dewpoint Therapeutics 
<a href="#michael-rosenblatt">Michael Rosenblatt</a>, CMO, Flagship Pioneering 
Session Leader: <a href="#selina-koch">Selina Koch</a>, Executive Editor, BioCentury
9:20 The Path to Acceleration 
A conversation between <a href="#clifford-hudis">Clifford Hudis</a>, CEO, American Society of Clinical Oncology and <a href="#michael-varney">Michael Varney</a>, Chairman of R&amp;D, ERASCA; Senior Advisor, Frazier Healthcare
9:40 Innovation That Matters 
A conversation between <a href="#robert-nelsen">Robert Nelsen</a>, Co-Founder and Managing Director of ARCH Venture Partners and <a href="#michael-martin">Michael Martin</a>, Global Head of Takeda Ventures
10:00 Day 1 Adjourns

Day 1 STATE OF INNOVATION 2021

8:00 Welcome 
<a href="#karen-chen">Karen Chen</a>, CEO, Spinal Muscular Atrophy Foundation 
<a href="#david-chang">David Chang</a>, CEO, WuXi Advanced Therapies, WuXi AppTec
8:05 Twenty Years of Progress in Cancer. What to Expect Next? 
A conversation between <a href="#jose-baselga">José Baselga</a>, EVP &amp; President, Oncology R&amp;D, AstraZeneca and <a href="#nina-kjellson">Nina Kjellson</a>, General Partner, Canaan Partners
8:25 The Aging and Brain Challenges: Are We at the Cusp of Breaking Through? 
<a href="#howard-federoff">Howard Federoff</a>, CEO, Aspen Neuroscience 
<a href="#howard-fillit">Howard Fillit</a>, Founding Executive Director and CSO, Alzheimer’s Drug Discovery Foundation 
<a href="#irene-griswold-prenner">Irene Griswold-Prenner</a>, CEO &amp; CSO, Nitrome Biosciences 
<a href="#rudolph-tanzi">Rudolph Tanzi</a>, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Vice-Chair, Neurology, MGH 
Session Leader: <a href="#barbara-dalton">Barbara Dalton</a>, Managing General Partner, Pfizer Ventures; VP Worldwide Business Development, Pfizer
9:05 Delivering the Promise of Cell and Gene Therapies 
<a href="#jeffrey-bluestone">Jeffrey Bluestone</a>, President &amp; CEO, Sonoma Biotherapeutics 
<a href="#steve-harr">Steve Harr</a>, President &amp; CEO, Sana Biotechnology 
<a href="#sekar-kathiresan">Sekar Kathiresan</a>, CEO, Verve Therapeutics 
<a href="#kartik-ramamoorthi">Kartik Ramamoorthi</a>, Co-Founder &amp; CEO, Encoded Therapeutics 
Session Leader: <a href="#edward-hu">Edward Hu</a>, Vice Chairman of the Board and Global Chief Investment Officer, WuXi AppTec
9:45 Day 2 Adjourns

Day 2 WHEN PAST MEETS FUTURE

8:00 Welcome 
<a href="#annette-bakker">Annette Bakker</a>, President, Children’s Tumor Foundation 
<a href="#richard-soll">Richard Soll</a>, Head of WuXi AppTec’s Boston Office; Senior Advisor of Strategic Initiatives
8:05 Shaping the Next Twenty Years 
<a href="#robert-califf">Robert Califf</a>, Head of Clinical Policy and Strategy for Verily and Google Health 
<a href="#aviv-regev">Aviv Regev</a>, Head, Genentech Research and Early Development 
Session Leader: <a href="#amir-nashat">Amir Nashat</a>, Managing Partner, Polaris Partners
8:30 The New Era of Medicines 
<a href="#chris-chen">Chris Chen</a>, CEO, WuXi Biologics 
<a href="#yvonne-greenstreet">Yvonne Greenstreet</a>, President &amp; COO, Alnylam Pharmaceuticals 
<a href="#nello-mainolfi">Nello Mainolfi</a>, Co-Founder, President &amp; CEO, Kymera Therapeutics 
<a href="#laura-shawver">Laura Shawver</a>, CEO, Silverback Therapeutics 
Session Leader: <a href="#john-carroll">John Carroll</a>, Chief Editor &amp; Founder, Endpoints News
9:10 When Technology Meets Healthcare 
<a href="#kate-bingham">Kate Bingham</a>, Managing Partner, SV Health Investors 
<a href="#david-jaffray">David Jaffray</a>, SVP, Chief Technology &amp; Digital Officer and Professor, University of Texas M.D. Anderson Cancer Center 
<a href="#vijay-pande">Vijay Pande</a>, General Partner, Andreessen Horowitz 
<a href="#daphne-zohar">Daphne Zohar</a>, Founder &amp; CEO, Member of the Board of Directors, PureTech Health                                         Session Leader: <a href="#michal-preminger">Michal Preminger</a>, Head, Johnson &amp; Johnson Innovation East North America
9:55 Closing Remarks 
<a href="#hui-cai">Hui Cai</a>, Forum Chair; VP and Head of Content Division, WuXi AppTec

Day 3 FROM SICK CARE TO HEALTH CARE

KV-1152×648

WuXi Global Forum 2021

REGISTRATION and NETWORKING

<a href="#hui-cai">Hui Cai</a>, Forum Chair, VP and Head of Content Division, WuXi AppTec

WELCOME

<a href="#ge-li">Ge Li</a>, Chairman, WuXi AppTec and WuXi Biologics

OPENING REMARKS

Are We Breaking New Ground? 
<a href="#david-schenkein">David Schenkein</a>, General Partner, GV 
Antoine Papiernik, Managing Partner, Sofinnova Partners 
<a href="#kristiina-vuori">Kristiina Vuori</a>, President, Sanford Burnham Prebys Medical Discovery Institute 
<a href="#edward-hu">Edward Hu</a>, Co-CEO, WuXi AppTec 
Moderator: <a href="#eric-elenko">Eric Elenko</a>, Chief Innovation Officer, PureTech Health
A Dialogue with Howard “Skip” Burris, President, ASCO; President of Clinical Operations and CMO, Sarah Cannon 
Moderator: <a href="#fred-hausheer">Fred Hausheer</a>, Global Chief Medical Officer and Head of WuXi Oncology, WuXi AppTec

SESSION I: STATE OF INNOVATION

Cell Therapies: Where Are We Heading? 
<a href="#richard-klausner">Richard Klausner</a>, Founder and CEO, Lyell Immunopharma 
<a href="#patrick-hwu">Patrick Hwu</a>, Head, Division of Cancer Medicine, MD Anderson Cancer Center 
Moderator: <a href="#karen-bernstein">Karen Bernstein</a>, Co-Founder and Chairman, BioCentury
Delivering the Promise of Gene Therapies 
<a href="#james-wilson">James Wilson</a>, Professor of Medicine and Pediatrics of Department of Medicine and Director of Gene Therapy Program, University of Pennsylvania 
<a href="#tachi-yamada">Tachi Yamada</a>, Venture Partner, Frazier Healthcare Partners 
Moderator: <a href="#john-carroll">John Carroll</a>, Editor and Founder, Endpoints News

SESSION II: SPOTLIGHT ON CELL AND GENE THERAPIES

A Dialogue with David Liu, Director of the Merkin Institute and Vice-Chair of the Faculty, Broad Institute; Professor of Harvard University and HHMI 
Moderator: Chris Chen, CEO, WuXi Biologics
Incremental or Transformative? 
<a href="#paul-peter-tak">Paul-Peter Tak</a>, President and CEO, Kintai Therapeutics 
<a href="#steve-paul">Steve Paul</a>, Chairman and CEO, Karuna Therapeutics 
<a href="#samantha-du">Samantha Du</a>, Chairman and CEO, Zai Lab 
<a href="#lalo-flores">Lalo Flores</a>, CEO, Century Therapeutics 
Moderator: <a href="#steve-yang">Steve Yang</a>, EVP and CBO, WuXi AppTec

SESSION III: RACE TO THE CURE

A Dialogue with Hans Bishop, CEO, GRAIL 
Moderator: <a href="#melinda-richter">Melinda Richter</a>, Global Head, Johnson &amp; Johnson Innovation, JLABS
How is Technology Shaping the Future of Healthcare? 
<a href="#jason-coloma">Jason Coloma</a>, President and CEO, Maze Therapeutics 
<a href="#zavain-dar">Zavain Dar</a>, Partner, Lux Capital 
<a href="#carolyn-magill">Carolyn Magill</a>, CEO, Aetion 
<a href="#john-halamka">John Halamka</a>, President, Mayo Clinic Platform 
<a href="#leon-wang">Leon Wang</a>, Executive VP International and China President, AstraZeneca 
Moderator: <a href="#kenneth-kaitin">Kenneth Kaitin</a>, Professor and Director, Tufts Center for the Study of Drug Development, Tufts University School of Medicine

SESSION IV: INNOVATION 2030

<a href="#steve-bates">Steve Bates</a>, CEO, UK BioIndustry Association

CLOSING REMARKS

RECEPTION

药明康德JMP-主KV－2020（RGB）

WuXi Global Forum 2020

<a href="#hui-cai">Hui Cai</a>, VP and Head of Content, WuXi AppTec, Program Chair

A conversation with <a href="#dietmar-berger">Dietmar Berger</a>, Head of Development and CMO, Sanofi; moderated by <a href="#kevin-da-silva">Kevin Da Silva</a>, Chief Editor, Nature Neuroscience

Session I: Meeting the Challenges in MS and Neuroscience Drug Development

<a href="#tanuja-chitnis">Tanuja Chitnis</a>, Professor of Neurology, Harvard Medical School; Director, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital 
<a href="#mark-freedman">Mark Freedman</a>, Professor of Neurology, University of Ottawa; Sr. Scientist, The Ottawa Hospital Research Institute 
<a href="#ari-green">Ari Green</a>, Chief, Division of Neuroinflammation and Glial Biology, Medical Director, Multiple Sclerosis and Neuroinflammation Center, UCSF 
<a href="#cyndi-zagieboylo">Cyndi Zagieboylo</a>, President and CEO, National MS Society 
Moderated by <a href="#mandy-jackson">Mandy Jackson</a>, Managing Editor of US Commercial News for Scrip and The Pink Sheet

Session II: Clinical Prospects for a Challenging Disease

<a href="#joachim-herz">Joachim Herz</a>, Professor, Molecular Genetics, Neuroscience, Neurology; Director, Center for Translational Neurodegeneration Research, UT Southwestern Medical Center 
<a href="#ralph-kern">Ralph Kern</a>, President and Chief Medical Officer, Brainstorm Cell Therapeutics 
<a href="#dan-lorrain">Dan Lorrain</a>, Chief Scientific Officer, Pipeline Therapeutics 
<a href="#krish-ramanathan">Krish Ramanathan</a>, Global Program Head, Neuroscience and Global Drug Development, Novartis 
Moderated by <a href="#richard-soll">Richard Soll</a>, Head of WuXi AppTec’s Boston office; Senior Advisor of Strategic Initiatives

Session III: New Directions in MS Therapies

As an industry enabler, WuXi AppTec is committed to improving the lives of patients globally. We share the conviction that we must work collaboratively to solve industry-wide challenges and bring transformative medicines to patients.
We welcome you to the conversation.

Events

EVENT RECAP

Fragile X Syndrome: In Pursuit of a Cure

Events

EVENT RECAP

Winning the War on Huntington’s Disease

Events

Progress in Halting Pompe Disease

Events

EVENT RECAP

WuXi Rare Disease Awareness Concert 2021

Events

EVENT RECAP

WuXi Healthcare Forum 2021

Events

WuXi AppTec Recognized by Frost & Sullivan with 2020 Global Customer Value Leadership Award

EVENT RECAP

WuXi Global Forum 2021

Events, WuXi Global Forum

EVENT RECAP

WuXi Global Forum 2020

WuXi Global Forum

Featured

Progress in Halting Pompe Disease

Events

WuXi Rare Disease Awareness Concert 2021

Events

WuXi Healthcare Forum 2021

Events

WuXi Global Forum 2021

Events, WuXi Global Forum

WuXi Global Forum 2020

WuXi Global Forum

Emerging Opportunities in Multiple Sclerosis and Neurosciences

Events